SpringWorks Therapeutics
Focus: SpringWorks Therapeutics is a mid-cap oncology biotech focused on small-molecule therapeutics with two approved products (OGSIVEO and GOMEKLI) generating 100% of revenue. The company operates from Stamford, CT with a focused portfolio in rare tumors and neurofibromatosis indications.
Profile data last refreshed 11h ago · AI intelligence enriched 3w ago
Open Jobs
7-3 this month
Stable — net -3 jobs in 30d
4 added, 7 removed. Backfill posture.
Should You Work at SpringWorks Therapeutics?
AI assessmentSpringWorks is a solid mid-stage biotech with approved products and a multi-indication pipeline, best suited for commercial and medical affairs professionals seeking growth-stage execution roles rather than early-stage drug discovery talent.
Why Work Here
- Two approved NDA products with extended LOE dates (OGSIVEO through 2043, GOMEKLI through 2044) provide multi-decade revenue visibility and job security.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$429K Part DGrowing
GROWTH
Help build intelligence for SpringWorks Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.